Medical Consumables and Lab Consumables OEM Manufacturer
Medical Consumables and Lab Consumables OEM Manufacturer

News & Events

10 2026.02
CARsgen Administers First Dose of Allogeneic CAR-T Therapy to Patient With Systemic Lupus Erythematosus
February 2026 — Global Biotech NewsShanghai, China / Global — CARsgen Therapeutics Holdings Ltd., a clinical-stage biotechnology company focused on innovative chimeric antigen receptor T-cell (CAR-T...
08 2026.02
Global Cell & Gene Therapy Industry Shows Strong Growth Across Approvals, Revenue and Deals
February 2026 — Industry NewsThe global cell and gene therapy (CGT) sector continues to expand, with recent industry data highlighting a combination of strong product revenues, increasing regulatory ...
06 2026.02
FDA Clears IND for AAV-Based Gene Therapy Targeting High-Grade Glioma
February 2026 — Global Biotech NewsSan Francisco, CA / USA — The U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) application for SRN-101, an AAV-based immuno-ge...
03 2026.02
FDA Officials Recommend Long-Term Follow-Up for CAR-T Therapies in Autoimmune Diseases
February 2, 2026 — Global Biotech NewsSilver Spring, MD, USA — Senior officials at the U.S. Food and Drug Administration (FDA) have urged biotechnology companies to implement long-term monitoring of...
30 2026.01
Sarepta Reports Positive Three-Year Data for Duchenne Gene Therapy Elevidys
January 2026Sarepta Therapeutics announced new three-year follow-up data showing that its Duchenne muscular dystrophy (DMD) gene therapy Elevidys (delandistrogene moxeparvovec) continued to demonstrat...
27 2026.01
Novo Nordisk Expands Diabetes Cell Therapy Partnership with Aspect Biosystems
January 25, 2026 — Global Biotech NewsCopenhagen, Denmark / Vancouver, Canada — Danish pharmaceutical giant Novo Nordisk A/S has announced an expansion of its strategic collaboration with Canadian...
23 2026.01
Groundbreaking Phase III Cell Therapy Trial for Parkinson’s Disease Begins Across Australia and North America
January 2026A pivotal Phase III cell therapy clinical trial evaluating a novel donor-derived dopamine-producing cell therapy has commenced enrollment across multiple countries, including Australia, Ca...
20 2026.01
Asia-Pacific Gene Therapy Market Poised to Reach US$14.59 Billion by 2033, Report Says
January 2026 — Industry NewsThe Asia-Pacific gene therapy market is projected to experience rapid growth over the next decade, with market size expected to reach approximately US$14.59 billion by 20...
18 2026.01
FDA Declines Approval of Atara’s Cell Therapy for Rare Blood Cancer
January 13, 2026The U.S. Food and Drug Administration (FDA) has declined to approve Atara Biotherapeutics’ cell therapy tabelecleucel for the treatment of Epstein-Barr virus positive post-transplant ...
16 2026.01
FDA Expands Regulatory Flexibility for Cell and Gene Therapy Development
January 2026The U.S. Food and Drug Administration (FDA) has announced an updated regulatory approach aimed at increasing flexibility in the development and manufacturing oversight of cell and gene the...
13 2026.01
NKGen Biotech's SNK02 Cellular Therapy Granted FDA Fast Track Designation for Refractory Solid Tumors
SANTA ANA, Calif., Jan. 10, 2026 – NKGen Biotech, Inc., a clinical-stage biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for...
11 2026.01
Johnson & Johnson Reaches Drug Pricing Deal with U.S. Government
Johnson & Johnson has reached an agreement with the U.S. government to lower prices on select prescription drugs, marking a significant development in ongoing negotiations between the pharmaceutic...